The biggest riser in small caps this week has been Trafalgar Property Group PLC (AIM:TRAF) and we wish we could tell you why, but if the company doesn’t, what chance do we have?
The week saw the company appoint Dr Paul Francis Challinor as chief executive, and if he is the reason for the 79% share price surge, he has a lot to do.
Dr. Challinor has been described by Trafalgar as a renowned and respected pioneer and executive director, specializing in the construction and management of indoor hydroponic vertical farming facilities and in the food safety sector.
The days when Ncondezi Energy Ltd (AIM:NCCL, OTC:NCDZF) was informally called Oopsidaisy may be over as the company’s share price rose 63% this week on news of a project solar and battery potential.
The Ncondezi Board of Directors has concluded an internal review of the 300 megawatt (MW) Ncondezi Integrated Power Project in Tete, Mozambique and believes there is potential for a solar power and storage project of grid-scale batteries at the project site.
Preliminary studies confirm that the project site benefits from favorable solar conditions – who knew that Mozambique was sunny? – and access to the Mozambican network.
The board believes that the solar project would be deliverable without compromising the main power project.
Wishbone Gold PLC (AIM:WSBN) jumped 26% this week as it launched an ‘asset survey’ of its Red Setter Gold-Copper project located 13km southwest of the Telfer gold mine in the Patersons Range in Western Australia.
The objective of this survey is to increase access to peripheral targets, beyond those already cleared, where drilling will begin in the coming weeks. The heritage survey will then move to the Cottesloe project located 55 km south-southwest of the Telfer gold mine, Wishbone said.
Shares of Immedia Broadcasting PLC jumped 23% to 24.5p following the company’s sale of its subsidiary Immediate Broadcast Limited. The company changed its name to Acquisition PLC, signifying its new life as a cash shell.
Financial advisory firm DSW Capital PLC (AIM:DSW) released its first business update since listing on AIM last December and it was a goodie, with the company reporting that revenue and adjusted profit before tax for the current year should be ahead of current market expectations. .
Tungsten Corp PLC (AIM:TUNG), the invoice processing company, has been on AIM for far longer than DSW – nearly 10 years – and it hasn’t been a particularly glorious stint, but shareholders should soon come out of their misery.
Listed at 225p, the board this week recommended acceptance of a 48p per share offer from Pagero which beat the 40p per share offer Kofax had fielded.
However, it may not be quite over yet, as Kofax considers its options and has urged Tungsten shareholders not to take any action in response to Pagero’s announcement.
Circassia Group PLC (AIM:CIR, OTC:CSSPF), a company engaged in the design, development and commercialization of medical devices for the diagnosis and management of asthma, applauded shareholders at the annual general meeting with an upbeat business statement.
Clinical revenues for the first four months of the year were above management’s expectations and up approximately 17% compared to the same period in 2021. Research revenues were also slightly higher than those of the previous year.
“We are aware that our business in China (14% of sales in 2021) may be affected by the local shutdowns that have taken place since late March, but it traded strongly in the first four months, generating superior growth. to 23% over the same period in 2021,” the company said.
Its sector counterpart Open Orphan PLC (AIM:ORPH, OTC:OPORF), a fast-growing specialist contract research organization, saw its shares rise 5.8% this week after drawing attention to a Key Considerations for the Development and Manufacture of Challenge Agents published in the Wellcome Open Research Journal.
The paper was co-authored by Alex Mann, senior director of clinical research at Open Orphan subsidiary hVIVO. The document is titled “Considerations on Principles of Development and Manufacturing Grades of Challenge Agents for Use in Human Infection Models”.
“As funders of global infectious disease research, Wellcome is pleased to support this clear and practical document for the development of challenge agents where GMP [good manufacturing practice] not possible. This guidance can ensure the full potential of studies of human infections around the world, which provide crucial information on infectious diseases, helping to rapidly accelerate vaccine development,” said Shobana Balasingam, Head of Infection Prevention Research. infectious diseases at Wellcome.